Basilea Pharmaceutica AG (BSLN.SW)

CHF 41.65

(0.24%)

Total Debt Summary of Basilea Pharmaceutica AG

Basilea Pharmaceutica AG's latest annual total debt in 2023 was 128.6 Million CHF , down -31.28% from previous year.
Basilea Pharmaceutica AG's latest quarterly total debt in 2024 Q2 was 95.68 Million CHF , down 0.0% from previous quarter.
Basilea Pharmaceutica AG reported annual total debt of 187.13 Million CHF in 2022, down -14.53% from previous year.
Basilea Pharmaceutica AG reported annual total debt of 218.95 Million CHF in 2021, down -9.64% from previous year.
Basilea Pharmaceutica AG reported quarterly total debt of 128.6 Million CHF for 2023 Q4, down 0.0% from previous quarter.
Basilea Pharmaceutica AG reported quarterly total debt of 169.77 Million CHF for 2023 Q2, down 0.0% from previous quarter.

Annual Total Debt Chart of Basilea Pharmaceutica AG (2023 - 2002)

Historical Annual Total Debt of Basilea Pharmaceutica AG (2023 - 2002)

Year	Total Debt	Total Debt Growth
2023	128.6 Million CHF	-31.28%
2022	187.13 Million CHF	-14.53%
2021	218.95 Million CHF	-9.64%
2020	242.31 Million CHF	22.54%
2019	197.74 Million CHF	0.38%
2018	196.98 Million CHF	0.39%
2017	196.22 Million CHF	0.63%
2016	195 Million CHF	0.0%
2015	195 Million CHF	0.0%
2014	- CHF	0.0%
2013	- CHF	-100.0%
2012	1.7 Million CHF	0.0%
2011	- CHF	0.0%
2010	- CHF	0.0%
2009	- CHF	0.0%
2008	- CHF	0.0%
2007	- CHF	0.0%
2006	- CHF	0.0%
2005	- CHF	-100.0%
2004	10.38 Million CHF	-4.87%
2003	10.91 Million CHF	-0.2%
2002	10.93 Million CHF	0.0%

Year	Total Debt	Total Debt Growth
2024 Q2	95.68 Million CHF	0.0%
2023 Q4	128.6 Million CHF	0.0%
2023 Q2	169.77 Million CHF	0.0%
2023 FY	128.6 Million CHF	-31.28%
2022 FY	187.13 Million CHF	-14.53%
2022 Q4	187.13 Million CHF	0.0%
2022 Q2	231.3 Million CHF	0.0%
2021 FY	218.95 Million CHF	-9.64%
2021 Q2	229.64 Million CHF	0.0%
2021 Q4	218.95 Million CHF	0.0%
2020 Q4	242.31 Million CHF	0.0%
2020 Q2	199.91 Million CHF	0.0%
2020 FY	242.31 Million CHF	22.54%
2019 Q2	197.35 Million CHF	0.0%
2019 FY	197.74 Million CHF	0.38%
2019 Q4	197.74 Million CHF	0.0%
2018 FY	196.98 Million CHF	0.39%
2018 Q4	196.98 Million CHF	0.0%
2018 Q2	196.6 Million CHF	0.0%
2017 Q4	196.22 Million CHF	0.0%
2017 Q2	195.84 Million CHF	0.0%
2017 FY	196.22 Million CHF	0.63%
2016 Q4	195.46 Million CHF	0.0%
2016 Q2	195.08 Million CHF	0.0%
2016 FY	195 Million CHF	0.0%
2015 Q2	- CHF	0.0%
2015 Q4	194.7 Million CHF	0.0%
2015 FY	195 Million CHF	0.0%
2014 FY	- CHF	0.0%
2014 Q4	- CHF	0.0%
2014 Q2	- CHF	0.0%
2013 Q2	- CHF	0.0%
2013 FY	- CHF	-100.0%
2013 Q4	- CHF	0.0%
2012 Q2	- CHF	0.0%
2012 FY	1.7 Million CHF	0.0%
2012 Q4	1.7 Million CHF	0.0%
2011 FY	- CHF	0.0%
2011 Q2	- CHF	0.0%
2011 Q4	- CHF	0.0%
2010 Q2	- CHF	0.0%
2010 FY	- CHF	0.0%
2010 Q4	- CHF	0.0%
2009 Q4	- CHF	0.0%
2009 FY	- CHF	0.0%
2008 FY	- CHF	0.0%
2007 FY	- CHF	0.0%
2006 FY	- CHF	0.0%
2005 FY	- CHF	-100.0%
2004 FY	10.38 Million CHF	-4.87%
2003 FY	10.91 Million CHF	-0.2%
2002 FY	10.93 Million CHF	0.0%

Peer Total Debt Comparison of Basilea Pharmaceutica AG

Name	Total Debt	Total Debt Difference
Addex Therapeutics Ltd	344.33 Thousand CHF	-37248.985%
BB Biotech AG	304.9 Million CHF	57.82%
Evolva Holding SA	- CHF	-Infinity%
Idorsia Ltd	1.2 Billion CHF	89.315%
Kuros Biosciences AG	5.51 Million CHF	-2230.663%
Molecular Partners AG	3.65 Million CHF	-3421.522%
Relief Therapeutics Holding AG	4.31 Million CHF	-2883.206%
Santhera Pharmaceuticals Holding AG	25.06 Million CHF	-413.151%